Lytix Biopharma AS (FRA:6BG)

Lytix Biopharma AS Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 23, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	62	57	34	17	30	53
Market Cap Growth	87.55%	66.98%	96.42%	-41.17%	-44.45%	-
Enterprise Value	56	50	31	10	13	32
Last Close Price	0.79	0.77	0.48	0.42	0.76	1.36
PS Ratio	-	-	36.05	48.79	28.19	27.59
PB Ratio	11.85	10.92	3.72	3.80	2.30	2.81
P/TBV Ratio	11.85	10.92	3.72	3.80	2.30	2.81
EV/Sales Ratio	-	-	32.39	29.06	12.63	16.76
Debt / Equity Ratio	0.04	0.04	0.02	0.01	0.01	0.01
Net Debt / Equity Ratio	-1.14	-1.14	-1.19	-0.97	-1.06	-1.03
Net Debt / EBITDA Ratio	1.10	1.10	1.34	0.52	2.19	4.11
Net Debt / FCF Ratio	1.17	1.17	1.82	0.52	2.73	4.37
Asset Turnover	-	-	0.11	0.04	0.06	0.16
Quick Ratio	4.28	4.28	3.90	5.01	8.51	14.29
Current Ratio	4.28	4.28	3.91	5.06	8.55	14.33
Return on Equity (ROE)	-70.71%	-70.71%	-118.41%	-94.33%	-34.54%	-45.90%
Return on Assets (ROA)	-35.09%	-35.09%	-56.97%	-55.72%	-22.90%	-25.23%
Return on Capital Employed (ROCE)	-101.70%	-101.70%	-87.40%	-188.40%	-48.50%	-25.10%
Earnings Yield	-8.20%	-8.89%	-23.48%	-45.14%	-18.03%	-9.03%
FCF Yield	-	-8.87%	-17.53%	-49.31%	-16.98%	-8.37%
Buyback Yield / Dilution	-26.05%	-26.05%	-35.05%	-1.01%	-19.50%	-26.57%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.